Chlorpromazine Hydrochloride

New Delhi: Drug makers Glenmark , Sun Pharma and Zydus are recalling products in the US for manufacturing issues, the US Food and Drug Administration ( USFDA ) said in its latest Enforcement Report. As per the US health regulator, Mumbai-based Glenmark is recalling over 25 products in the US market due to Current Good Manufacturing Practice (CGMP) deviations. New Jersey-based Glenmark Pharmaceuticals Inc is recalling affected lots of medications like Propafenone Hydrochloride extended-release capsules and Solifenacin Succinate Tablets in America, the USFDA said. It is also recalling products like Voriconazole Tablets, Lacosamide Tablets, Frovatriptan Succinate Tablets and Rufinamide Tablets. The company initiated the Class II recall on March 13 this year. As per the USFDA, a Class-II recall is initiated when the use of, or exposure to, a violative product may lead to temporary or medically reversible health consequences, or when the likelihood of serious adverse health outcomes is minimal. A US-based subsidiary of Sun Pharma is recalling around 13,700 bottles of Gabapentin capsules, a medication used to treat and prevent seizures in people with epilepsy. New Jersey-based Sun Pharmaceutical Industries Inc is recalling the affected lot due to 'Cross Contamination', the USFDA said. The company initiated the Class III recall on March 4, 2025. The US health regulator said Zydus Pharmaceuticals (USA) Inc is recalling 3,144 bottles of chlorproMAZINE Hydrochloride Tablets, USP 10 mg, a medication used to treat mental health conditions, like schizophrenia and bipolar disorder. The drug firm is recalling the affected lot due to CGMP deviations , the USFDA said. There was "presence of N-Nitroso-Desmethyl Chlorpromazine impurity above the recommended interim limit," it added. The company initiated the Class II recall on April 3, 2025.

New Delhi: Drug firms Glenmark and Biocon are recalling products in the US for manufacturing issues, according to the US health regulator. In its latest Enforcement Report , the US Food and Drug Administration ( USFDA ) stated that a US-based unit of the Mumbai-based drug firm is recalling a medication to treat various ailments like schizophrenia and anxiety. New Jersey-based Glenmark Pharmaceuticals Inc is recalling 8,160 bottles of chlorpromazine hydrochloride tablets in the US for "CGMP deviations", USFDA stated. "Results of the finished product is above the agency's current recommended limit of a Nitrosamine , N-Nitroso-Desmethyl Chlorpromazine impurity," it added. The company initiated the Class II nationwide (US) recall on March 11 this year. USFDA stated that US-based Biocon Pharma Inc is recalling 2,184 bottles of a medication to treat high cholesterol. The company is recalling the affected lot due to "failed dissolution specifications", the US health regulator said. The company initiated the Class II recall on March 17, 2025. As per the USFDA, a Class-II recall is initiated when the use of, or exposure to, a violative product may lead to temporary or medically reversible health consequences, or when the likelihood of serious adverse health outcomes is minimal. Shares of Glenmark ended 4.35 per cent down to Rs 1,376.35 apiece on the BSE on Wednesday. Biocon shares, on the other hand, ended 5.33 per cent down at Rs 305.20 apiece on the BSE.